TABLE 1.
Characterization of NLC formulations with respect to size, zeta potential, and EE.
| Sr.No. | Solid lipids or Transcutol | Method used | Zeta potential | Particle size | PDI | EE (%) |
|---|---|---|---|---|---|---|
| 1 | GMS | Homogenization (NLC-1) | −14.78 ± 2.1 | 230 ± 10.4 | 0.254 | 70.28 ± 2.4 |
| 2 | SA | Homogenization (NLC-1) | −13.38 ± 1.1 | 161 ± 8.9 | 0.211 | 75.8 ± 2.3 |
| 3 | CA | Homogenization (NLC-1) | −14.2 ± 0.9 | 205 ± 9.8 | 0.190 | 65.54 ± 1.9 |
| 4 | GMS | Probe sonication (NLC-2) | −16.8 ± 2.2 | 342 ± 13.4 | 0.311 | 66.34 ± 1.5 |
| 5 | SA | Probe sonication (NLC-2) | −13.9 ± 1.7 | 351 ± 17.8 | 0.281 | 71.20 ± 2.1 |
| 6 | CA | Probe sonication (NLC-2) | −12.9 ± 0.8 | 311 ± 15.4 | 0.275 | 62.29 ± 1.7 |
| 7 | GMS | Sonication with homogenization (NLC-3) | −15.42 ± 2.8 | 219.1 ± 9.2 | 0.217 | 74.90 ± 2.2 |
| 8 | SA | Sonication with homogenization (NLC-3) | −13.58 ± 1.8 | 151.5 ± 11.5 | 0.218 | 69.90 ± 3.2 |
| 9 | CA | Sonication with homogenization (NLC-3) | −11.35 ± 1.3 | 187.5 ± 5.2 | 0.233 | 80.90 ± 2.6 |